Anti-VEGF Innovations in Retinal Disease
Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.
A recent Ophthalmology Times Case-Based Roundtable® discussed the structural differences among newer second-generation anti-VEGF agents and their implications for clinical efficacy and treatment durability.
- Real-world experiences and evidence regarding extended treatment intervals and sustained disease control with these newer therapies were highlighted.
- A case of an 83-year-old woman with diabetic macular edema (DME) was described by Stewart, MD.
She had undergone temporal grid laser photocoagulation for macular edema and received bevacizumab (Avastin; Genentech, Inc) intravitreal injections every 4 to 6 weeks.
Author's summary: Emerging anti-VEGF agents improve retinal disease treatment.
More News
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Tomago’s slow death exposes folly of ‘Made in Australia’ dream
- Can Hollywood Get Veterans Right—and Could It Actually Save Lives?
- Auto loan fraud growing among low-risk auto borrowers
- Trump Serenaded With Anthem YMCA as He Lands in South Korea
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- Record Job Cuts at Amazon and UPS. AI and Reorganization Changing the Face of Logistics
- The UK needs regulation – but we can do it an awful lot better